acf/google-ad-placement

Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

News

C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today presented clinical data from the ongoing Phase 1 trial of

C4 Therapeutics Presented Cemsidomide Phase 1 Data At ASH Meeting; Said In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36% ORR, 45% CBR; In Non-Hodgkin's Lymphoma, Cemsidomide Monotherapy Demonstrated 38% ORR, 19% CMR - C4 Therapeutics (NASDAQ:CCCC)

Benzinga Newsdesk

C4 Therapeutics

CCCC

C4 Therapeutics Presented Cemsidomide Phase 1 Data At ASH Meeting; Said In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36% ORR, 45% CBR; In Non-Hodgkin's Lymphoma, Cemsidomide Monotherapy Demonstrated 38% ORR, 19% CMR

Comments